MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- NOVARTIS - MYLAN (US)
NOVARTIS vs MYLAN (US) - Comparison Results
NOVARTIS Change
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 NOVARTIS  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NOVARTIS Mar-19 |
MYLAN Dec-18 |
NOVARTIS/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 980 | 3,549 | - | |
| Low | Rs | 600 | 1,953 | - | |
| Sales per share (Unadj.) | Rs | 198.7 | 1,633.1 | - | |
| Earnings per share (Unadj.) | Rs | 21.0 | 44.3 | - | |
| Cash flow per share (Unadj.) | Rs | 22.3 | 350.1 | - | |
| Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.3 | 0 | - | |
| Book value per share (Unadj.) | Rs | 307.5 | 1,766.7 | - | |
| Shares outstanding (eoy) | m | 24.69 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.0 | 1.7 | 236.0% | |
| Avg P/E ratio | x | 37.7 | 62.0 | 60.7% | |
| P/CF ratio (eoy) | x | 35.5 | 7.9 | 451.8% | |
| Price / Book Value ratio | x | 2.6 | 1.6 | 165.0% | |
| Dividend payout | % | 47.7 | 0 | - | |
| Avg Mkt Cap | Rs m | 19,508 | 1,415,525 | 1.4% | |
| No. of employees | `000 | 0.6 | 35.0 | 1.7% | |
| Total wages/salary | Rs m | 1,171 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,445.4 | 24,006.2 | 35.2% | |
| Avg. wages/employee | Rs Th | 2,015.7 | 0 | - | |
| Avg. net profit/employee | Rs Th | 891.0 | 651.9 | 136.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,907 | 840,217 | 0.6% | |
| Other income | Rs m | 783 | 0 | - | |
| Total revenues | Rs m | 5,689 | 840,217 | 0.7% | |
| Gross profit | Rs m | 123 | 217,417 | 0.1% | |
| Depreciation | Rs m | 32 | 157,322 | 0.0% | |
| Interest | Rs m | 16 | 40,412 | 0.0% | |
| Profit before tax | Rs m | 858 | 19,684 | 4.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 340 | -3,132 | -10.9% | |
| Profit after tax | Rs m | 518 | 22,815 | 2.3% | |
| Gross profit margin | % | 2.5 | 25.9 | 9.7% | |
| Effective tax rate | % | 39.6 | -15.9 | -249.2% | |
| Net profit margin | % | 10.6 | 2.7 | 388.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 8,055 | 469,176 | 1.7% | |
| Current liabilities | Rs m | 1,850 | 342,081 | 0.5% | |
| Net working cap to sales | % | 126.4 | 15.1 | 835.9% | |
| Current ratio | x | 4.4 | 1.4 | 317.4% | |
| Inventory Days | Days | 45 | 84 | 53.9% | |
| Debtors Days | Days | 34 | 93 | 36.3% | |
| Net fixed assets | Rs m | 150 | 162,988 | 0.1% | |
| Share capital | Rs m | 123 | 447 | 27.6% | |
| Net worth | Rs m | 7,592 | 908,961 | 0.8% | |
| Long term debt | Rs m | 0 | 981,060 | 0.0% | |
| Total assets | Rs m | 9,824 | 2,438,187 | 0.4% | |
| Interest coverage | x | 54.9 | 1.5 | 3,694.7% | |
| Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 144.9% | |
| Return on assets | % | 5.4 | 2.6 | 209.4% | |
| Return on equity | % | 6.8 | 2.5 | 271.7% | |
| Return on capital | % | 11.5 | 3.2 | 361.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | -1,943 | 174,597 | -1.1% | |
| From Investments | Rs m | 2,742 | -90,247 | -3.0% | |
| From Financial Activity | Rs m | -298 | -81,338 | 0.4% | |
| Net Cashflow | Rs m | 501 | 1,446 | 34.7% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.56 Rs / USD
Compare NOVARTIS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare NOVARTIS With: TTK HEALTHCARE PANACEA BIOTECH J.B.CHEMICALS SHASUN PHARMA WYETH
Today's Market
6 Reasons Why Sensex Plunged 1,708 Points Today(Closing)
Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.
Related Views On News
NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
More Views on NewsMost Popular
A Critical Update on the Market (Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy (Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers (Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More
